Inotek’s glaucoma treatment fails late-stage study

(Reuters) – Inotek Pharmaceuticals Corp said its experimental glaucoma treatment failed a late-stage study, citing a stronger-than-expected placebo effect. The company’s stock slumped 64.8 percent to $2.15 in premarket trading on Tuesday and was set for its worst day ever. Inotek’s lead drug, trabodenoson, was no better than a placebo in reducing fluid pressure in the eye in patients with the most common form of glaucoma or ocular hypertension.
Go to Source